|
|||||
|
|
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor,in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification |
|
| Authors: | Sai-Hong Ignatius Ou Eunice L Kwak Christina Siwak-Tapp Joni Dy Kristin Bergethon Jeffrey W Clark D Ross Camidge Benjamin J Solomon Robert G Maki Yung-Jue Bang Dong-Wan Kim James Christensen Weiwei Tan Keith D Wilner Ravi Salgia A John Iafrate |
| Institution: | 2. Massachusetts General Hospital Cancer Center, Boston, Massachusetts;3. University of Colorado Cancer Center, Aurora, Colorado;4. Peter MacCallum Cancer Center, Melbourne, Australia;5. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;11. Department of Pathology. Massachusetts General Hospital, Boston, Massachusetts |
| Abstract: | Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor. |
| Keywords: | Non-small cell lung cancer Crizotinib (PF02341066) |
| 本文献已被 ScienceDirect 等数据库收录！ | |